A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors

By sjmartinez • March 27, 2025

Eng C, Lakhani NJ, Philip PA, Schneider C, Johnson B, Kardosh A, Chao MP, Patnaik A, Shihadeh F, Lee Y, Song K, Jin D, Huo Y, Howland M, Fisher GA, Hecht JR. A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors. Target Oncol. 2025 Mar 26. doi: 10.1007/s11523-025-01130-y. Epub ahead of print. PMID: 40140179.

Tags: Hematology/Oncology, Publications

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis

Zaorsky NG, Sun Y, Nabid A, Zapatero A, Bolla M, Joseph D, Maingon P, Guerrero A, Gonzalez AA, San-Segundo CG, Cabeza Rodríguez MÁ, Sole JM,[...]

Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer

Barnes DR, Tyrer JP, Dennis J, Leslie G, Bolla MK, Lush M, Aeilts AM, Aittomäki K, Andrieu N, Andrulis IL, Anton-Culver H, Arason A, Arun[...]

Oncoplastic Breast Surgery: Optimizing Resection Margins in Addition to Aesthetic Outcomes

Yesantharao PS, Shaheen MS, Hui G, Gombar S, Momeni A. Oncoplastic Breast Surgery: Optimizing Resection Margins in Addition to Aesthetic Outcomes. Aesthetic Plast Surg. 2025[...]